

COUNTRY LEVEL DATA

Spain



DATA FOR: **Spain** 

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

COUNTRY: Spain

COUNTRY:	Spain				
		DEMOGRA	APHICS:		
	<u>Spain</u>	<u>EUROPE</u>	Age_	<u>Spain</u>	<u>EUROPE</u>
Total number of responses	284	4375	Up to 25	5.3%	6.4%
•			26 to 35	14.4%	17.9%
<u>Gender</u>	<u>Spain</u>	<u>EUROPE</u>	36 to 45	31.7%	27.4%
Man	3.9%	3.7%	46 to 55	32.0%	26.6%
Woman	93.7%	95.6%	56 to 65	12.3%	14.8%
Other / prefer not to answer	2.5%	0.7%	above 65	3.2%	5.1%
Total	100.0%	100.0%	NA	1.1%	1.8%
			Grand Total	100.0%	100.0%
		DIAGN	OSIS		
<u>Diagnosis</u>	<u>Spain</u>	<u>EUROPE</u>	<u>Time to Diagnosis</u>	<u>Spain</u>	EUROPE
SLE	94.4%	94.4%	Within the year	24.5%	26.5%
Child onset SLE	5.6%	5.6%	1 year	20.2%	21.1%
Grand Total	100.0%	100.0%	2 years	17.1%	11.5%
			3 years	5.8%	5.7%
Prior Diagnosis received before "Lupus"	<u>Spain</u>	<u>EUROPE</u>	4 years	6.6%	4.6%
None	47.9%	53.7%	5 years	4.3%	4.4%
UCTD/MCTD	2.8%	6.7%	6 years	2.3%	2.9%
Sjogren	5.3%	4.7%	7 years	2.3%	2.7%
APS	3.2%	2.4%	8 years	3.5%	2.4%
Other Autoimmune or Rheumatic	14.8%	13.8%	9 years	1.9%	2.3%
Fibromyalgia	4.6%	5.8%	10 to 20 years	8.6%	10.4%
Psychologic or mental disorder	9.9%	8.9%	More than 20 years	2.7%	5.5%
Other prior diagnosis	22.5%	16.5%	Grand Total	100.0%	100.0%
n=	269	4,275	n=	257	4,154



DATA FOR: **Spain** 

IMPACT ON STUDIES & CAREER							
Education level	<u>Spain</u>	<u>EUROPE</u>	Employment level	<u>Spain</u>	<u>EUROPE</u>		
Basic	12.5%	3.7%	Employed full time	33.1%	34.6%		
Secundary	49.8%	53.9%	Employed part time	12.0%	16.5%		
Academic	37.6%	42.5%	Self-employed full time	4.7%	3.0%		
n=	271	4,150	Self-employed part time	0.0%	2.4%		
			Looking for employment	10.2%	5.1%		
Economic profile	<u>Spain</u>	<u>EUROPE</u>	Stopped work for medical reason	14.5%	14.7%		
No difficulties paying all bills	50.0%	46.9%	Retired	12.0%	11.6%		
Occasional difficulties paying all bills.	22.2%	26.8%	Student	4.0%	4.0%		
Often difficulties paying all bills	9.5%	10.4%	No paid employment / Full time home	4.7%	4.7%		
Always difficulty paying all bills	10.9%	7.1%	Other / prefer not to answer	4.7%	3.5%		
Did not respond	7.4%	8.9%					
n=	284	4375	n=	275	4247		
IMPACT ON STUDIES	<u>Spain</u>	<u>EUROPE</u>	IMPACT ON CAREER	<u>Spain</u>	<u>EUROPE</u>		
Chose more relevant studies	3.7%	3.1%	No impact	45.0%	32.5%		
could not do what they wanted	9.2%	11.1%	Changed career/ job	7.1%	13.5%		
needed special support and received it	1.5%	4.6%	moved to Flexible hours	7.1%	8.1%		
needed support but did NOT receive it	3.3%	2.9%	Reduced Work Schedule	6.3%	18.5%		
Overall negative effect	14.3%	13.5%	Stopped work, gets social allowances	13.9%	18.5%		
Overall positive effect	1.5%	1.4%	Missed promotion opportunities	9.2%	9.5%		
No impact	71.1%	69.8%	Employment was terminated	8.4%	8.4%		
			Other negative impact	23.1%	20.8%		
n=	273	4240	Other positive impact	2.9%	1.8%		
			Overall had negative impact	47.9%	57.9%		
			n=	238	4024		



DATA FOR: **Spain** 

			IMPACT ON SOC	IAL / FAMILY		
Civil status		Spain	EUROPE	Have children	Spain	EUROPE
Child/young with family		4.1%	4.5%	None	34.4%	32.8%
Single		17.0%	17.4%	One child	26.1%	23.8%
Married / with partner		67.4%	66.9%	2 or more children	35.5%	38.9%
Divorced		10.0%	9.2%	Child/young living with family	4.0%	4.5%
Widowed		1.5%	2.0%	S, 10 a 8	,	
	n=	270	4206	n=	276	4288
Would have liked more children		<u>Spain</u>	<u>EUROPE</u>	Faced Misscariages	<u>Spain</u>	EUROPE
A. Yes		46.2%	37.6%	A. One miscarriage	15.0%	18.4%
B. No		30.7%	37.7%	B. Some miscarriages	5.3%	8.5%
C. don't know / prefer not to answer		23.1%	24.7%	C. Many miscarriages	1.2%	2.9%
				D. No miscarriage	78.5%	70.2%
n (women c	only) =	199	3,645	n (women only) =	246	3,756
Difficulty to cope with Daily activities		<u>Spain</u>	<u>EUROPE</u>	More or less active than others same age	<u>Spain</u>	EUROPE
No Problem at all 1		18.5%	16.2%	Less active due to lupus	72.2%	72.6%
2		30.9%	32.3%	Equally active	14.3%	15.6%
3		33.8%	34.3%	More active due to lupus	4.8%	3.6%
4		14.2%	15.4%	I don't know	8.8%	8.1%
Fully Unable 5		2.5%	1.8%			
	n=	275	4226	n=	273	4212
Impact on Sexual/emotional life		<u>Spain</u>	<u>EUROPE</u>	Negative Impact on couple	<u>Spain</u>	EUROPE
Negative impact		40.9%	38.2%	It created tensions	36.0%	33.2%
Mixed Positive and negative		32.8%	36.2%	It is difficult for me	67.7%	68.4%
No significant impact		26.3%	23.9%	It is difficult for my partner	26.5%	26.7%
Positive impact		0.0%	1.6%	I am concerned for my couple	15.3%	13.2%
				Our relationship ended	12.2%	16.6%
	n=	274	4,204	n=	189	2875



DATA FOR: **Spain** 

DISEASE ACTIVITY							
Lunus was under control past 2 mont	·hc	Spain	ELIDODE	Number of symptoms (list of 22)	Snain	ELIDODE	
Lupus was under control past 3 mont	.115	<u>Spain</u>	EUROPE	Number of symptoms (list of 23)	Spain 1 50/	EUROPE 1.60/	
Yes		77%	72%	1	1.5%	1.6%	
No		23%	28%	2	1.1%	2.1%	
				3	2.9%	4.4%	
	n=	281	4347	4	5.9%	5.9%	
				5	9.2%	6.1%	
				6	10.3%	8.5%	
		<u>Spain</u>	<u>EUROPE</u>	7	9.9%	9.3%	
Average nr of symptoms (list of 23)			8.8	8	11.0%	10.4%	
	n=	272	4197	9	10.7%	10.1%	
				10	8.8%	9.3%	
				11	8.5%	8.3%	
		<u>Spain</u>	<u>EUROPE</u>	12	8.8%	7.0%	
Median number of symptoms		8	9	13	4.0%	5.8%	
	n=	272	4197	14	1.5%	4.4%	
				15	2.2%	2.7%	
				16	1.5%	2.1%	
						1.1%	
						0.4%	
						0.3%	
						0.0%	
Average nr of symptoms (list of 23)  Median number of symptoms		8.5 272 <u>Spain</u> 8	8.8 4197 <u>EUROPE</u> 9	8 9 10 11 12 13 14	11.0% 10.7% 8.8% 8.5% 8.8% 4.0%	10.4 10.1 9.3 8.3 7.0 5.8 4.4 2.7 2.1 1.1 0.4 0.3	



DATA FOR: **Spain** 

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

## Symptoms or Features experienced / Most bothersome

	Spai	n		EURO	)PF
	Regularly	Top 3 most		Regularly	Top 3 most
Patient reported Symptoms or features	experience	bothersome	Patient reported Symptoms or features	experience	bothersome
A. Rash	30%	5%	A. Rash	40%	9%
B. Sun sensitivity	69%	25%	B. Sun sensitivity	69%	23%
C. Mouth ulcers	42%	6%	C. Mouth ulcers	35%	3%
D. Dryness in the mouth or eyes	53%	9%	D. Dryness in the mouth or eyes	55%	9%
E. Dryness of the skin	55%	2%	E. Dryness of the skin	57%	4%
F. Hair loss	55%	9%	F. Hair loss	53%	14%
G. Pain / swelling in joints	82%	56%	G. Pain / swelling in joints	77%	49%
H. Jaccoud (hand deformation) or tendons a	16%	2%	H. Jaccoud (hand deformation) or tendor	14%	4%
I. Muscle Pain/Weakness	72%	38%	I. Muscle Pain/Weakness	68%	33%
J. Headaches or migraine	49%	18%	J. Headaches or migraine	51%	17%
K. Fatigue and weakness	78%	39%	K. Fatigue and weakness	85%	55%
L. Flu-like symptoms/Fevers	24%	4%	L. Flu-like symptoms/Fevers	28%	4%
M. Shortness of breath	18%	6%	M. Shortness of breath	32%	6%
N. Depression or Anxiety	46%	17%	N. Depression or Anxiety	44%	17%
O. Haematologic problems incl. anemia	35%	5%	O. Haematologic problems incl. anemia	27%	4%
P. Poor circulation or Raynauds	44%	11%	P. Poor circulation or Raynauds	45%	8%
Q. Kidney problems	22%	13%	Q. Kidney problems	20%	11%
R. Chest pain	23%	5%	R. Chest pain	24%	4%
S. High Blood pressure	17%	3%	S. High Blood pressure	23%	4%
T. Stroke, mini-stroke, Blood clots	6%	5%	T. Stroke, mini-stroke, Blood clots	9%	4%
U. Osteoporosis	17%	7%	U. Osteoporosis	19%	5%
n=	284	263	n=	4375	4084



DATA FOR: **Spain** 

MEDICATION							
	<u>Spain</u>	<u>EUROPE</u>		<u>Spain</u>	EUROPE		
Average number of medication (from list	<u>Spain</u>	LONOFE	Median number of medication (from	<u>Spain</u>	LOKOFL		
-	ГА	гэ		F	г		
<u>of 16)</u>	5.4	5.2	<u>list of 16)</u>	5	5		
n=	261	4099	n=	261	4099		
Number of medications (list of 16)	<u>Spain</u>	<u>EUROPE</u>	% using given medication type:	<u>Spain</u>	<u>EUROPE</u>		
1	4.2%	5.4%	Non Steroids Anti-Inflammatory	43.3%	32.9%		
2	9.6%	9.0%	Antimalarials	80.8%	75.0%		
3	10.7%	12.5%	Oral Steroids	51.3%	52.4%		
4	13.8%	14.1%	Immunosuppressants	41.8%	39.8%		
5	13.0%	14.8%	Biologics	15.3%	10.9%		
6	12.6%	13.9%	Painkillers	51.7%	50.1%		
7	12.6%	11.8%	Antidepressant	19.5%	17.0%		
8	11.9%	9.0%	Anxiolytic	26.1%	11.7%		
9	6.9%	5.1%	Anticoagulants	18.8%	16.6%		
10	3.1%	2.5%	Thyroid medication	12.3%	14.8%		
11	1.5%	1.1%	Blood circulation and heart	18.0%	23.3%		
12	0.0%	0.4%	Stomach protection	57.5%	47.0%		
13	0.0%	0.2%	Statins	4.6%	5.9%		
			Calcium	33.3%	29.7%		
n=	261	4099	Vitamin D		68.4%		
			Vitamins (excl.D) / mineral complements	10.3%	25.4%		



DATA FOR: **Spain** 

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

# ACCESS / Quality of life (scale of 1 to 5)

I have appropriate access to	<u>Spain</u>	<u>EUROPE</u>	HrQoL dimensions	Spain <u>EU</u>	<u>JROPE</u>		
Average scores (1 Fully disagree	- 5 fully agree)		AVERAGE SCORES (1=FULLY ABLE, 5= FULLY UNABLE)				
Experienced lupus doctors	4.02	3.81	Mobility	2.02	2.22		
Multidisciplinary team	3.51	3.28	Self care	1.60	1.71		
Specialised nurses that know lupus	2.71	2.92	Daily Activities	2.51	2.54		
Prescribed medication	4.53	4.08	Pain or discomfort	3.23	3.14		
Affordable treatments	4.20	3.77	Anxiety or depression	3.04	2.96		
Social support and benefits	2.63	2.78	Average	2.48	2.51		
Physiotherapy, Rehab, Occupational Thera	2.30	2.77					
Professional psychological support	2.75	2.68					
n min	212	3126	n min	273	4196		
n max	241	3842	n max	276	4240		
Worry about lupus progressing?	<u>Spain</u>	<u>EUROPE</u>					
Very Low (1-2)	2.7%	3.6%					
Low (3-4)	5.5%	9.3%					
Mid (5-6)	25.0%	24.5%					
High (7-8)	39.8%	41.0%					
Very high (9-10)	27.0%	21.6%					
n=	256	4042					



DATA FOR: **Spain** 

Publication: <a href="http://dx.doi.org/10.1136/lupus-2020-000469">http://dx.doi.org/10.1136/lupus-2020-000469</a>

## Impact of lupus not being under control over past 3 months

	% (	of Health Related	OoL Maintaine	ed vs 100% = FULL HEALTH/ABILITY TO PERFORM		_
		Spain		· · · · · · · · · · · · · · · · · · ·	<u>EURO</u>	PE
		lupus under	not under		lupus under	not under
		<u>control</u>	<u>control</u>		<u>control</u>	<u>control</u>
Mobility		77%	67%	Mobility	73%	59%
Self care		87%	80%	Self care	86%	73%
Daily Activities		65%	53%	Daily Activities	66%	51%
Pain or discomfort		46%	37%	Pain or discomfort	51%	35%
Anxiety or depression		53%	36%	Anxiety or depression	54%	44%
Average		65%	54%	Average	66%	52%
	n min	210	62	n min	3011	1179
	n max	211	64	n max	3042	1194
		Spain			EURO	PE
		lupus under	not under	More or less active than others of same	lupus under	not under
More or less active than others of same	age	control	control	age	control	control
Less active due to lupus		69.9%	79.4%	Less active due to lupus	68.6%	83.0%
Equally active		16.3%	7.9%	Equally active	18.8%	7.6%
More active due to lupus		4.8%	4.8%	More active due to lupus	4.0%	2.7%
I don't know		9.1%	7.9%	I don't know	8.7%	6.7%
	n=	209	63	n=	3018	1189
		Spain			EURO	PE
		lupus under	not under		lupus under	not under
Impact on Sexual/emotional life		control	control	Impact on Sexual/emotional life	control	control
Negative impact		38.1%	50.8%	Negative impact	34.0%	49.0%
Mixed + and -		32.9%	33.3%	Mixed + and -	36.4%	35.7%
No significant impact		29.0%	15.9%	No significant impact	27.8%	14.1%
Positive impact		0.0%	0.0%	Positive impact	1.8%	1.2%
·	n=	210	63	n=	3018	1181



DATA FOR: **Spain** 

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

#### **IMPACT OF A PROMPT DIAGNOSIS**

#### % of Health Related QoL Maintained vs 100% = FULL HEALTH/ABILITY TO PERFORM

	<u>Spa</u>	<u>in</u>		EURO	<u>DPE</u>
		<u>Diagnosed</u>		<u>Diagnosed</u>	<u>Diagnosed</u>
	<u>Diagnosed</u>	after more		within 2	after more
	within 2 years	than 5 years		<u>years</u>	than 5 years
Mobility	80%	67%	Mobility	75%	62%
Self care	89%	79%	Self care	86%	76%
Daily Activities	67%	53%	Daily Activities	67%	53%
Pain or discomfort	49%	35%	Pain or discomfort	52%	39%
Anxiety or depression	52%	42%	Anxiety or depression	52%	49%
Average	67%	55%	Average	66%	56%
Difference		-12%	Difference		-10%
of which - explained by age (*)		-2%	of which - explained by age		-3%
	112	CE	- main	1026	1220
n min	113	65	n min	1926	1239
n max	114	66	n max	1951	1249
average age:	42.8	48.6		41.2	49.0


<sup>(\*)</sup> in our overall study, we found that from age 28 to age 63 HrQOL drops from 69.1% to 56.0% i.e. 3.7% per decade





DATA FOR: Spain


Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0












DATA FOR: Spain

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0







Living with lupus in 2020 - Country level data

DATA FOR: 0

For full text european analysis, please refer to:

Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Science & Medicine 2021;8:e000469. doi:10.1136/lupus-2020-000469

For more informatioin, contact: secretariat@lupus-europe.org